Across TCGA pan-cancer cohorts, NCKIPSD Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NCKIPSD data layer compared with 21 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher NCKIPSD Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NCKIPSD expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

KIRP, LUSC, and ESCA are the cancer types where NCKIPSD Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	OS	Median	All	0.270	0.904	<.001	12	view →
LUSC	OS	Median	III,IV	0.086	0.684	<.001	12	view →
ESCA	OS	Median	II,III,IV	0.321	0.685	.035	6	view →
SKCM	OS	Median	II,III,IV	1.000	0.303	.021	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: NCKIPSD tumor-vs-normal RNA expression · all NCKIPSD data types